US Branded Drug Invoice Price Increases Moderate In 2016
Executive Summary
Price increases before rebates and other concessions stayed below double digits in 2016, as manufacturers responded to public and political pressure on pricing practices, the QuintilesIMS annual drug spending report shows.
You may also be interested in...
Cost Sharing Fight: PhRMA Says Insurance Design Is Real Pricing Culprit
New report finds increase in use of deductibles and coinsurance charging members list prices.
Big Pharma’s Unlikely Price Pledge Leader
Allergan is taking a page from Big Pharma’s strategy two decades ago to fend off efforts at direct price regulation by pledging restraint on price increases. The differences in the pledge – and the image of the pledge maker – are instructive.
Price Concessions By Manufacturers To Payers Rose Sharply In 2015
Net spending on all drugs rose 8.5% to $310bn in the US in 2015 when discounts, rebates and other price concessions are considered, annual IMS review says.